Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_assertion type Assertion NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_head.
- NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_assertion wasGeneratedBy ECO_0000203 NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_provenance.
- NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_assertion wasDerivedFrom befree-20140225 NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_provenance.
- NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_assertion SIO_000772 21387358 NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_provenance.
- NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_assertion evidence source_evidence_literature NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_provenance.
- NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_assertion description "[Of the 121 AMLs with clinical history, there were no significant differences in 4-year event-free survival (EFS) (46% vs. 38%; p = 0.46) and overall-survival (OS) (55% vs. 43%; p = 0.30) between FLT3-wildtype and ITD+ patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP202312.RAeXn2dsKd6et5aDXT8fyDN05i8jQXvDSEOO3-_Xw2su4130_provenance.